DE60010722D1 - Dibenzopyrane als glucocorticoid-rezeptor-antagonisten für die behandlung von zuckerkrankheit - Google Patents
Dibenzopyrane als glucocorticoid-rezeptor-antagonisten für die behandlung von zuckerkrankheitInfo
- Publication number
- DE60010722D1 DE60010722D1 DE60010722T DE60010722T DE60010722D1 DE 60010722 D1 DE60010722 D1 DE 60010722D1 DE 60010722 T DE60010722 T DE 60010722T DE 60010722 T DE60010722 T DE 60010722T DE 60010722 D1 DE60010722 D1 DE 60010722D1
- Authority
- DE
- Germany
- Prior art keywords
- dibenzopyrans
- treatment
- receptor antagonists
- glucocorticoid receptor
- sugar disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38825199A | 1999-09-01 | 1999-09-01 | |
US388251 | 1999-09-01 | ||
PCT/US2000/024234 WO2001016128A1 (en) | 1999-09-01 | 2000-09-01 | Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60010722D1 true DE60010722D1 (de) | 2004-06-17 |
DE60010722T2 DE60010722T2 (de) | 2005-05-12 |
Family
ID=23533319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60010722T Expired - Lifetime DE60010722T2 (de) | 1999-09-01 | 2000-09-01 | Dibenzopyrane als glucocorticoid-rezeptor-antagonisten für die behandlung von zuckerkrankheit |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1208095B1 (de) |
JP (1) | JP2003508393A (de) |
AR (1) | AR034096A1 (de) |
AT (1) | ATE266655T1 (de) |
AU (1) | AU7109000A (de) |
BR (1) | BR0009320A (de) |
CA (1) | CA2381239A1 (de) |
CO (1) | CO5180649A1 (de) |
DE (1) | DE60010722T2 (de) |
DK (1) | DK1208095T3 (de) |
ES (1) | ES2220529T3 (de) |
HK (1) | HK1047580B (de) |
MX (1) | MXPA02002110A (de) |
PT (1) | PT1208095E (de) |
WO (1) | WO2001016128A1 (de) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6593480B2 (en) * | 1999-09-01 | 2003-07-15 | Abbott Laboratories | Glucocorticoid receptor antagonists for treatment of diabetes |
US7235662B2 (en) | 2003-06-11 | 2007-06-26 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
WO2006072599A2 (en) | 2005-01-10 | 2006-07-13 | Glaxo Group Limited | Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
AR053346A1 (es) | 2005-03-25 | 2007-05-02 | Glaxo Group Ltd | Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38 |
UY29439A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
PE20071068A1 (es) | 2005-12-20 | 2007-12-13 | Glaxo Group Ltd | Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3 |
MX2008013411A (es) | 2006-04-20 | 2008-11-04 | Glaxo Group Ltd | Nuevos compuestos. |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
TW200820977A (en) | 2006-08-08 | 2008-05-16 | Organon Nv | Use of glucocorticoid receptor antagonists for treatment of infectious conditions |
PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
BRPI0912267A2 (pt) | 2008-05-23 | 2015-10-13 | Amira Pharmaceuticals Inc | sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável. |
ES2383246T3 (es) | 2008-06-05 | 2012-06-19 | Glaxo Group Limited | 4-amino-indazoles |
WO2009147187A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
ES2745628T3 (es) | 2008-11-07 | 2020-03-03 | Univ Sheffield | Medicamento y método de diagnóstico |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
EP2408769A1 (de) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Als itk-inhibitoren verwendete pyrimidinderivate |
CN102439151A (zh) | 2009-03-19 | 2012-05-02 | 默沙东公司 | 使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制 |
EP2408458A1 (de) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | Rna-schnittstellen-vermittelte unterdrückung der signal transducer and activator of transcription 6 (stat6) genexpression mit short interfering nucleic acid (sina) |
US20120016011A1 (en) | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
JP2012520685A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害 |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
JP2012521764A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害 |
WO2010111497A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2411019A2 (de) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | Rna-interferenz-vermittelte hemmung der signal transducer and activator of transcription 1 (stat1) gen-expression mittels sina (short interfering nucleic acid) |
JP2012524755A (ja) | 2009-04-24 | 2012-10-18 | グラクソ グループ リミテッド | Cracチャネル阻害剤としてのn−ピラゾリルカルボキサミド |
WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
US8575162B2 (en) | 2009-04-30 | 2013-11-05 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
JP2013512879A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体 |
EP2507226A1 (de) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Neuartige verbindungen |
WO2011067366A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
EP2512438B1 (de) | 2009-12-16 | 2017-01-25 | 3M Innovative Properties Company | Formulierungen und verfahren zur steuerung der mdi-partikelgrössenfreisetzung |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
WO2012032065A1 (en) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
HUE026059T2 (en) | 2010-09-08 | 2016-05-30 | Glaxosmithkline Ip Dev Ltd | N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
WO2012052458A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
JP2013544794A (ja) | 2010-10-21 | 2013-12-19 | グラクソ グループ リミテッド | アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物 |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
WO2012123312A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
MY184292A (en) | 2013-09-22 | 2021-03-30 | Sunshine Lake Pharma Co Ltd | Substituted aminopyrimidine compounds and methods of use |
US20160256466A1 (en) | 2013-10-17 | 2016-09-08 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
CA2925064A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
WO2015148867A1 (en) | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
SG11201609276RA (en) | 2014-05-12 | 2016-12-29 | Glaxosmithkline Ip No 2 Ltd | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
EP3347097B1 (de) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
WO2018029126A1 (en) | 2016-08-08 | 2018-02-15 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
JP2023519585A (ja) | 2020-03-26 | 2023-05-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ウイルス感染を予防または治療するカテプシン阻害剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2091721B (en) * | 1980-10-20 | 1984-02-15 | Erba Farmitalia | 6-substituted 6h-dibezo(b,d)pyran derivatives and process for their preparation |
TR200003094T2 (tr) * | 1998-02-13 | 2001-01-22 | Abbott Laboratories | Glukokortikoid-seçimli enflamasyon önleyici maddeler. |
-
2000
- 2000-08-30 CO CO00065017A patent/CO5180649A1/es not_active Application Discontinuation
- 2000-08-31 AR ARP000104550A patent/AR034096A1/es not_active Application Discontinuation
- 2000-09-01 PT PT00959835T patent/PT1208095E/pt unknown
- 2000-09-01 AT AT00959835T patent/ATE266655T1/de not_active IP Right Cessation
- 2000-09-01 AU AU71090/00A patent/AU7109000A/en not_active Abandoned
- 2000-09-01 CA CA002381239A patent/CA2381239A1/en not_active Abandoned
- 2000-09-01 ES ES00959835T patent/ES2220529T3/es not_active Expired - Lifetime
- 2000-09-01 DK DK00959835T patent/DK1208095T3/da active
- 2000-09-01 JP JP2001519695A patent/JP2003508393A/ja not_active Withdrawn
- 2000-09-01 WO PCT/US2000/024234 patent/WO2001016128A1/en active IP Right Grant
- 2000-09-01 MX MXPA02002110A patent/MXPA02002110A/es not_active Application Discontinuation
- 2000-09-01 EP EP00959835A patent/EP1208095B1/de not_active Expired - Lifetime
- 2000-09-01 DE DE60010722T patent/DE60010722T2/de not_active Expired - Lifetime
- 2000-09-01 BR BR0009320-3A patent/BR0009320A/pt not_active IP Right Cessation
-
2002
- 2002-10-17 HK HK02107584.5A patent/HK1047580B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PT1208095E (pt) | 2004-09-30 |
WO2001016128A1 (en) | 2001-03-08 |
DE60010722T2 (de) | 2005-05-12 |
ATE266655T1 (de) | 2004-05-15 |
EP1208095B1 (de) | 2004-05-12 |
CO5180649A1 (es) | 2002-07-30 |
BR0009320A (pt) | 2002-02-05 |
MXPA02002110A (es) | 2002-11-07 |
ES2220529T3 (es) | 2004-12-16 |
DK1208095T3 (da) | 2004-09-20 |
AU7109000A (en) | 2001-03-26 |
HK1047580B (zh) | 2005-04-01 |
AR034096A1 (es) | 2004-02-04 |
JP2003508393A (ja) | 2003-03-04 |
HK1047580A1 (en) | 2003-02-28 |
EP1208095A1 (de) | 2002-05-29 |
CA2381239A1 (en) | 2001-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60010722D1 (de) | Dibenzopyrane als glucocorticoid-rezeptor-antagonisten für die behandlung von zuckerkrankheit | |
ATE304530T1 (de) | Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen | |
DE60230773D1 (de) | Harnstoff-derivate als vanilloid-rezeptor-antagonisten für die schmerzbehandlung | |
ATE551340T1 (de) | Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten | |
DE60130675D1 (de) | Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose | |
DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
DE60108754D1 (de) | Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum | |
DE60309909D1 (de) | Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen | |
DE60329123D1 (de) | Benzoädüazepinderivate für die behandlung von neurologischen krankheiten | |
ATE374196T1 (de) | Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen | |
NO20034122L (no) | Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte | |
DE60236218D1 (de) | CCR5 Antagonisten verwendbar für die Behandlung von Aids | |
DE69927823T2 (de) | Hydrogel für die therapeutische behandlung von aneurysmas | |
TR200102021T2 (tr) | TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları | |
DE60226702D1 (de) | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen | |
DE60024649D1 (de) | Verbindungen für die behandlung von ischämie | |
ATE345331T1 (de) | Verbindungen verwendbar für die behandlung von entzündungskrankheiten | |
DE69829558D1 (de) | Sulfonamide für die behandlung von störungen durch endothelin vermittelt | |
DE60032823D1 (de) | Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen | |
ATE286895T1 (de) | Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten | |
ATE502642T1 (de) | Kombinationen für die behandlung von immun- entzündlichen erkrankungen | |
NO20016246D0 (no) | Selektiv iGluR5 reseptorantagonist for behandling av migrene | |
ATE422498T1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
MA26779A1 (fr) | Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central. | |
ATE260278T1 (de) | 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: KARO BIO AB, HUDDINGE, SE |
|
8364 | No opposition during term of opposition |